Abstract
SARS Vaccine Protective in Mice
Highlights
We have developed an inactivated virus vaccine that induces neutralizing antibodies and protects against SARS-CoV challenge
Immunogenicity of the vaccine was tested by immunizing BALB/c mice at 0, 2, and 4 weeks with 5 μg of inactivated virus combined with the adjuvant MF59, an oil squalene-in-water emulsion [6] approved for human use in Europe for an influenza vaccine
IgG subclass determination indicated a predominant Th2-type immune response similar to that observed in BALB/c mice vaccinated with a UVinactivated SARS-CoV plus alum [7]
Summary
9. Morré SA, Ossewaarde JM, Lan J, van Doornum GJ, Walboomers JM, MacLaren DM, et al Serotyping and genotyping of genital Chlamydia trachomatis isolates reveal variants of serovars Ba, G, and J as confirmed by omp1 nucleotide sequence analysis. We have developed an inactivated virus vaccine that induces neutralizing antibodies and protects against SARS-CoV challenge. Immunogenicity of the vaccine was tested by immunizing BALB/c mice at 0, 2, and 4 weeks with 5 μg of inactivated virus combined with the adjuvant MF59, an oil squalene-in-water emulsion [6] approved for human use in Europe for an influenza vaccine.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
